How should capital read San Diego in 2026: as a Tier 1 life sciences recovery market, a defense-and-cross-border industrial niche, a coastal multifamily income hold, or a place where selectivity within every asset class is the entire thesis?

San Diego is a multi-cluster specialty market, not a broad growth market and not a gateway play in the traditional sense. As of Q4 2025 / Q1 2026, it deserves capital attention for three specific reasons and skepticism about a fourth. Life sciences is the defining cluster — a 27.3M SF Tier 1 market mid-correction, with a 10.2% Torrey Pines vacancy sitting alongside a 39.7% Sorrento Mesa vacancy that tells the whole story about where oversupply lives. Industrial is digesting a prolonged spec cycle but posted its first meaningful positive absorption quarter in Q1 2026, anchored by Otay Mesa cross-border demand. Coastal multifamily remains the cleanest defensive income trade in the market given geography-constrained supply. Office is the asset class to avoid broadly and approach narrowly — the Torrey Pines corridor (3.5% vacancy) and Del Mar Heights ($4.68/SF/month) are structurally different markets from a downtown that is bleeding at 35.8% vacancy. Capital that cannot execute with submarket precision should stay out of San Diego entirely; capital that can should find real opportunities across at least three of the four asset classes.

• San Diego is the only U.S. market with a top-tier life sciences cluster, a significant defense-aerospace institutional demand floor, a cross-border industrial submarket with genuine structural trade volume, and a geography-constrained coastal multifamily market — all in the same metro. That combination does not exist in Boston, Phoenix, or Dallas.
• The Torrey Pines / UCSD / Scripps / Salk corridor is one of the most defensible anchor ecosystems in U.S. life sciences. FDA-credentialed facilities have switching costs that exceed relocation economics for most occupiers. Per Life Sciences and Lab Underwriting, renewal probability on cGMP manufacturing nodes exceeds 90%.
• Defense and MRO demand (NASSCO shipbuilding, Northrop Grumman, L3Harris, multiple Navy and Marine installations) creates an industrial demand floor that is completely uncorrelated with biotech venture cycles or e-commerce demand. This is structural, not cyclical.
• The national lab pipeline collapse — from 15.4M SF spec starts in 2022 to 2.4M SF in 2025 — is the most important supply-side number in the current life sciences cycle. The correction is already becoming self-limiting. San Diego was the second-largest U.S. lab cluster at the peak of oversupply; it is still the third-largest by inventory, and no new spec supply is being added. For long-duration core lab investors, the entry window is widening.
• $3.3B in VC funding reached San Diego life sciences companies in 2024 (third-highest globally). NIH funding exceeded $1B to San Diego organizations in FY 2024. The demand-side institutional base has not left; it contracted from a boom-era peak.
• Multifamily scarcity is geography-enforced, not policy-enforced. The Pacific Ocean, the coastal mountains, and the Mexican border create a supply wall that no zoning change can fully remove. This makes San Diego's 5.4% overall vacancy structurally more defensible than equivalent vacancy in inland Sun Belt markets with open land.

• Do not average across the life sciences market. The Torrey Pines/Sorrento Mesa spread — 10.2% versus 39.7% vacancy — is the most important single data point in the market. Investors underwriting "San Diego life sciences" as a uniform beta trade will own Sorrento Mesa exposure without knowing it.
• The Q4 2025 Savills update noted that five former Pfizer buildings could push Torrey Pines wet lab availability toward ~45%. That is a near-term supply event in the tightest submarket in the county — track the Pfizer building disposition carefully before making any new Torrey Pines lab investments.
• Do not treat the industrial Q1 2026 absorption inflection as a full market turn. Otay Mesa drove +851,435 SF of the +250,483 SF county-wide figure in Q1 2026 — the math is correct because Otay Mesa positive absorption more than offset other county-level negative trends. Otay Mesa vacancy is 12.2% with $1.08/SF/month asking rent; that is a tenant's market, not a landlord's market. The inflection is real but fragile.
• Office vacancy methodology differences are material. C&W reports 14.6% metro-wide versus Newmark's 20.2% (broader universe including flex/R&D). Downtown vacancy is 27.9% by C&W and 35.8% by Kidder Mathews using a broader CBD definition. The headline number is less important than knowing which submarket you are actually underwriting.
• Multifamily Class A vacancy at 10.2% versus overall 5.4% (Q3 2025, Matthews) mirrors the life sciences story: new speculative supply is the stress vector, not broad demand erosion. Capital targeting stabilized existing product is in a different market than capital chasing newly delivered luxury towers.
• Asking rent momentum across all asset classes is negative. Lab rents fell for 14 consecutive quarters. Industrial rents fell -3.9% YoY. Office rents fell -1.4% (all classes) and -1.5% (Class A). Multifamily rent growth was +0.2%. This is not a market that rewards broad income growth assumptions in underwriting.

San Diego fits capital that combines deep cluster conviction with submarket precision. The strongest profiles are:

• Selective core lab investors with long duration, institutional-quality sponsors, and patience for life sciences absorption cycles. Torrey Pines and UTC are the right submarkets; Sorrento Mesa at attractive basis is a value-add story that requires clear leasing roadmaps.
• Defense-linked industrial owner-user capital that can anchor to institutional MRO, shipbuilding, or aerospace demand without depending on e-commerce or cross-border speculation for IRR.
• Core coastal multifamily income buyers who value geography-enforced supply constraint over near-term rent growth. This is a hold-and-collect market, not a lease-up market.
• Opportunistic office capital underwriting specific distressed assets in Downtown at sub-$200/SF with a clear conversion or repositioning playbook. This is not a trophy-office acquisition market for most buyers at current pricing — it is a distressed resolution market at the CBD end.
• Long-duration cross-border industrial capital willing to hold Otay Mesa at current basis ($1.08/SF/month) for the structural maquiladora and nearshore manufacturing story, with underwriting that does not require immediate rent recovery.

Capital that does not fit: broad industrial beta seekers, spec lab developers without a named tenant, broadly diversified office acquirers, and any buyer treating San Diego as a single uniform market narrative.

San Diego's life sciences correction is tracking the Boston pattern. Boston-Cambridge vacancy reached 28.8% at year-end 2025; San Diego reached 28.6% in Q4 2025. Both markets experienced the same post-2021 supply-cycle reset. Both retain structural cluster depth that weaker markets (Raleigh-Durham at 32.3% vacancy, with fewer anchor-tenant stickiness mechanisms) do not replicate in the same way. See National Life Sciences Capital Allocation 2026 for the cross-cluster comparison table.

Per Life Sciences Cluster Geography, the national spec pipeline collapse to 2.4M SF in 2025 from 15.4M SF peak creates a multi-year absorption runway for both Boston and San Diego once demand stabilizes. The difference is that San Diego also has the defense/industrial and border-industrial theses working simultaneously, which gives it more allocation dimensions than a pure lab play.

San Diego is not part of the Sun Belt growth story in the same way as Phoenix, Atlanta, or Nashville. It is a coastal specialty market with a more concentrated demand base and more constrained land position. See Sun Belt Geography Hub for comparison context.

• Analyses Hub
• San Diego
• National Life Sciences Capital Allocation 2026
• Life Sciences Cluster Geography
• Life Sciences and Lab Underwriting
• Boston CRE Capital Allocation 2026
• Sun Belt Geography Hub
• CRE Investment Strategy
• Office Bifurcation

• San Diego Market Intelligence 2025-2026 — Cushman & Wakefield Q3 2025 life sciences (metro vacancy 26.5%, submarket breakdown); Savills Q4 2025 life sciences (28.6% overall, Class A rent $5.86/SF/month); CBRE Global Life Sciences Atlas (inventory 27.3M SF, under construction 1.6M SF); Newmark Q3 2025 life sciences (asking rent $5.37/SF/month NNN); Cushman & Wakefield Q4 2025 industrial (vacancy 7.2%, asking rent $1.47/SF/month NNN, net absorption +592,753 SF); Kidder Mathews Q1 2026 industrial (vacancy 9.6%, Otay Mesa absorption +851,435 SF); Newmark Q4 2025 industrial (rent growth -3.9% YoY); Matthews Real Estate Q3 2025 multifamily (vacancy 5.4%, rent $2,500/unit, 8,700 units under construction, cap rate 4.7%); Cushman & Wakefield Q4 2025 office (vacancy 14.6%, Class A rent $3.87/SF/month FSG, annual leasing 3.1M SF); Kidder Mathews Q4 2025 office (Downtown 35.8%, Torrey Pines 3.5%, Del Mar Heights $4.68/SF/month, 10-submarket breakdown).